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Simple Summary: The MYC oncoprotein is deregulated in up to 70% of human tumors and has a
crucial role in the initiation, progression, and maintenance of the tumorigenic process. The MYC
modulator MNT belongs to the MXD family of MYC antagonists and transcriptional repressors.
It differs from the other MXD family members due to its essential role in the cell and its diverse
and complex functions that can either facilitate or impair MYC-driven tumorigenesis. As MYC is
a difficult therapeutic target, increasing our knowledge of other proteins in the MYC network will
provide the basis for alternative strategies to impair MYC activity in cancer.
Abstract: MNT is a crucial modulator of MYC, controls several cellular functions, and is activated
in most human cancers. It is the largest, most divergent, and most ubiquitously expressed protein
of the MXD family. MNT was first described as a MYC antagonist and tumor suppressor. Indeed,
10% of human tumors present deletions of one MNT allele. However, some reports show that MNT
functions in cooperation with MYC by maintaining cell proliferation, promoting tumor cell survival,
and supporting MYC-driven tumorigenesis in cellular and animal models. Although MAX was
originally considered MNT’s obligate partner, our recent findings demonstrate that MNT also works
independently. MNT forms homodimers and interacts with proteins both outside and inside of
the proximal MYC network. These complexes are involved in a wide array of cellular processes,
from transcriptional repression via SIN3 to the modulation of metabolism through MLX as well as
immunity and apoptosis via REL. In this review, we discuss the present knowledge of MNT with a
special focus on its interactome, which sheds light on the complex and essential role of MNT in cell
biology.
Keywords: MNT; MYC; MAX; REL; transcriptional regulation; proliferation; cancer
1. Introduction
The discovery of MNT (MAX’s Next Tango) was reported by two independent labo-
ratories in 1997. One group found MNT through a two-hybrid screening in yeasts using
a murine cDNA library with MAX as the bait [1], while the other group isolated MNT
(originally called ROX) in a search for transcribed sequences of the human chromosome
17p13.3 [2].
The MNT transcription factor belongs to the MXD family (originally called MAD),
which shares a basic helix–loop–helix–leucine zipper (bHLHLZ) domain as well as a SIN3
interaction domain (SID). The bHLHLZ is necessary for forming dimers with MAX and for
binding to DNA on E-boxes (Enhancer-boxes). The SID establishes the interaction with
SIN3 proteins, facilitating transcriptional repression (see below) [3,4]. Notably, the SID
repressor domain linked to Cas9 has been described as an efficient tool in CRISPR-mediated
repression of targeted genes [5]. The canonical MXD proteins are MXD1, MXI1, MXD3,
and MXD4. There is yet another member, MGA [6], that shows little similarity with the
other MXDs, as it lacks the SID but binds to MAX through its bHLHLZ domain. MGA
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is a very large protein (3065 amino acids) and besides the bHLHLZ, it contains a T-box
domain, which is described in Brachyury proteins and is a characteristic of the TBX (T-Box)
transcription factor family. Its structure allows the regulation of both MAX-network and
T-domain target genes, either as an activator or repressor [6–8]. Inactivation of MGA is
frequent in human cancer, and a recent study has demonstrated that MGA functions as a
tumor suppressor in murine models of lung carcinoma and in colorectal cancer organoids,
partly due to the de-repression of MYC target genes [9].
MNT is a unique member of the MXD family due to several features; it is (i) the
largest protein of the family; (ii) the most divergent gene in its sequences; (iii) ubiquitously
expressed in human tissues; (iv) essential for mouse development; (v) expressed in both
quiescent and proliferating cells; (vi) altered in human cancer; and (vii) is frequently
involved in tumorigenesis (Table 1). It also plays an important role in modeling the
oncogenic activities of MYC, as an antagonist in some models or as a cooperator in others
(reviewed in [10]).
Table 1. Main differences between the human MNT, other human MXD proteins, MGA, and MYC. The sizes of the proteins
are the largest canonical forms, according to the UniProt database. Aa, amino acids; ND, not done; DEL, deletions; AMP,
amplifications; MUT, mutations; CTCL, Cutaneous T-cell lymphoma; MB, medulloblastoma; SS, Sezary Syndrome; ALL,
acute lymphoblastic leukemia.
MNT MXD1 MXI1 (MXD2) MXD3 MXD4 MYC References
Protein size 582 aa 221 aa 228 aa 206 aa 209 aa 439 aa Uniprotdatabase
P-rich
sequences Yes No No No No Yes [2]
Phenotype of
KO mice
Perinatally
lethal/
Craniofacial
abnormalities
Viable/Increased
immature
granulocyte
progenitors
Viable/
Hyperplasia
Viable/
Enhanced
sensitivity to
apoptotic
stimuli
ND
Embryonic
lethal
E9.5–E10.5
[11–14]
Proximal
MYC Network
interactors
MNT, MAX,
MLX MAX, MLX MAX MAX MAX, MLX MAX
Reviewed in
[15]
Expression in
cells
Quiescent and
proliferating Quiescent
Quiescent and
proliferating *
Proliferating
(S-phase) Quiescent Proliferating
Reviewed in
[15]
Pan-cancer
copy number
alterations (%)
DEL 10
AMP 3
MUT 1
DEL 2
AMP 6
MUT < 0.5
DEL 8
AMP 4
MUT < 0.5
DEL 7
AMP 8
MUT < 0.5
DEL 6
AMP 5
MUT < 0.5
DEL 2
AMP 21
MUT 1
[16]
Involvement
in human
cancer
DEL in
CTCL-SS and
ALL. Reduced
expression in
MB
None or weak None or weak None or weak None or weak
Strongly, 70%
of tumors have
deregulation
[17–22]
* central nervous system, epidermis, and the myeloid lineage.
MNT is evolutionarily conserved, an argument for its relevant role in cell biology. It
is the sole MXD protein identified in the fly Drosophila melanogaster [23]. Flies express a
“minimal” network composed of dMax, a single MYC protein (dMyc), and a sole MXD
protein (dMnt). In general, MNT and MXD1 are present along the phylogenetic tree,
whereas the other MXD are only present in vertebrates (reviewed in [15]). Interestingly,
dMnt is recruited to a higher number of Drosphila genes than dMyc is [24]. MNT or-
thologues are found in primitive pluricellular organisms from the Cnidaria (Hydra spp.,
Nemastotella spp.) and Placozoa (Trichoplax spp.) phylum [25]. In contrast, the nematodes
C. elegans, C. briggsae, and Brugia malayi lack MNT or MYC orthologs. However, these
species, together with the trematode Schistosoma mansoni, present orthologs for MAX, MLX,
MXD, and MLXIP [15,25,26].
In contrast to the other members of the MXD family, MNT is an essential protein
during development, as Mnt knockout mice die soon after birth [11,27]. Mice with null
homozygous deletions for Mxd1, Mxd2, or Mxd3 show different defects [12,13,28] but
survive to adult ages. Mnt-deficient embryos exhibit small size throughout development
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and, interestingly, show reduced levels of c-Myc and N-Myc [11]. Mnt-overexpressing
embryos also have developmental defects, are of a smaller size, and have decreased
cellularity [1]. These data suggest that a tight control of MNT levels is necessary for the
correct development.
2. MNT Structure and Regulation
The MNT gene is localized at human chromosome 17p13.3 and mouse chromosome
11B5. The human gene is 1.7 kb long and contains six exons according to the NCBI Gene
browser (GRCh38/hg38). Human MNT encodes a 582-amino acid protein that contains (i) a
coiled-coil α-helix structure for interaction with SIN3 (SID); (ii) a highly proline-rich region,
similar to the activation domains of other transcription factors like MYC; (iii) a bHLHLZ
domain, for homodimerization, interaction with MAX and MLX, and DNA-binding at
E-boxes, and (iv) a proline and histidine-rich region at its C-terminal domain [1,2]. Proline-
rich regions are usually involved in protein–protein interactions [29] and are typical of
transcriptional activation domains and are absent in the other MXD proteins. The SID
is necessary for the repressive function of MNT, as its deletion turns the protein into a
transcriptional activator [1]. We recently described that the C-terminal domain of MNT
(amino acids 306–537) is necessary for its interaction with REL [30], a member of the NF-κB
family. The MNT, MYC, MXD1, MAX, and MLX proteins are schematized in Figure 1A.
The MNT gene, protein, and its main interactors are shown in Figure 1B.
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Figure 1. MNT and MYC protein structure. (A) Comparison between YC, MXD1, MNT, MAX, and
MLX protein sizes and domains. The canonical isoforms are shown; specifically, the p22 isoform
for MAX and the gamma isoform for MLX. MYC boxes are represented in blue with the numbers
I–IV. (B) The MNT gene structure is s hematized at the top, with boxes representing the six exons,
and a scheme f the MNT protein at the bottom. The MNT exons that n od the most important
regions are indicated as boxes, and the dotted lines connect the exons with the corresponding protein
domains. The main MNT-interacting proteins are shown at the bottom. SID: SIN3 interacting domain;
P-rich: proline-rich sequence; bHLH: basic helix–loop–helix; LZ: leucine zipper; P-H-rich: proline
and histidine-rich region; DCD: dimerization and cytoplasmic localization domain. Figures were
created with BioRender.com (Toronto, ON, Canada).
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The basic region of MNT differs from the other bHLHLZ proteins in the proximal MYC
network, and MNT–MAX dimers show a higher preference for non-canonical CACGCG
E-boxes though they can also bind to the canonical CACGTG [2]. This difference in the
basic regions of the DNA explains why MNT has a subset of unique target genes apart
from the ones shared with MYC and the other MXDs.
MNT is a mainly nuclear protein with a half-life of 30–60 min, and it appears as a
doublet of 72–74 kDa in Western blots [1,2]. The 72 kDa form is the form detected in
growth-arrested cells. In contrast, MNT is detected at 74 kDa in serum-stimulated cells
and corresponds to the hyperphosphorylated protein. This phosphorylation is conducted
by MKK/ERK kinases and impairs the interaction with SIN3B and, consequently, the
repressive function of MNT [31]. So far, no other post-translational modifications have
been described for MNT except for ubiquitination (described below) [30].
3. MNT Expression
MNT mRNA is expressed in most human tissues according to a massive RNA-
sequencing study [32]. MNT mRNA levels were highest in the bone marrow, brain, en-
dometrium, spleen, and testis, while the lowest levels were in the heart, liver, pancreas,
and salivary glands. The GTEX database gives a more restricted pattern of MNT mRNA
expression in human tissues, peaking in the esophagus, intestine, and pancreas (Figure 2).
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Mnt is broadly expressed during mouse development. Its mRNA has already been de-
tected in early conceptus and in multiple tissues during development (informatics.jax.org/
marker/MGI:109150) until stage E10.5. At later stages, Mnt expression is the highest in
neural structures [1].
During Xenopus laevis development, the MNT orthologue XMnt is expressed in early
embryos at the neurula stage and in migrating cranial neural crest cells [33]. The expression
of Mnt in the neural tissues of mice and Xenopus seems consistent with the cleft palates
and craniofacial deformities observed in Mnt-deficient mice [11,34]. In Xenopus, XMnt,
XMad1, and XMad3 exhibit distinct areas of expression during embryogenesis, suggesting
non-redundant functions [33].
Both quiescent cells and fibroblasts express MNT throughout the cell cycle. MNT
levels do not increase upon serum stimulation of quiescent cells [31]. This is in contrast
with the expression pattern of MYC (expressed mainly in proliferating cells) and most
other MXD proteins, such as MXD1, MXI1, and MXD4 (mainly expressed in quiescent
cells). Thus, MNT–MAX dimers coexist with MYC–MAX in proliferating cells [1]. MNT
represses its own expression in a MAX-dependent manner by direct binding to its promoter.
E-box 2, which is mapped at −788 bp from the transcription start site, is critical for this
autoregulation. A decrease or absence of MAX results in high levels of MNT, which are
distributed among cytoplasm and nucleus. MNT also binds weakly to its own promoter
in the absence of MAX [35]. The presence of E-boxes in the MNT promoter indicates that
other bHLHLZ proteins could also control its expression.
MNT protein levels are also regulated by the E6-associated protein (E6AP), an E3
ubiquitin ligase that induces its ubiquitination and degradation by the proteasome. This
was observed in myeloid differentiation experiments, in which all-trans retinoic acid,
vitamin D3, or phorbol 12-myristate 13-acetate downregulated E6AP and consequently
reduced the E6AP-mediated degradation of MNT [30].
4. MNT Interactions in the Proximal MYC Network
The proximal MYC network is composed of thirteen proteins distributed into three
protein families: MYC, MXD, and MLXIP. The MYC family includes c-MYC (also called
MYC), MYCN (or N-MYC), and MYCL (or L-MYC). MAX connects MYC with the MXD
proteins while MLX connects the MXD with the MLXIP (also known as MONDO) proteins.
A scheme of this network is shown in Figure 3.
In contrast to the MYC and the MXD proteins, MNT can form homodimers. This
was initially discovered in yeast two-hybrid assays and with recombinant proteins [1,2].
More recently, the formation of MNT dimers has been shown in rat and human cell
lines. Yet, MNT–MAX complexes are formed preferentially to MNT–MNT dimers [35].
Electrophoretic mobility shift assay (EMSA) assays with in vitro synthesized proteins also
showed that MNT–MNT can bind to E-boxes but with a lower affinity compared to MNT–
MAX [2]. Importantly, it has been shown that MNT homodimers not only bind DNA, but
they are also able to regulate gene transcription [35].
In summary, MNT can form heterodimers with MAX [1,2], heterodimers with MLX [36],
or homodimers [35] through the bHLHLZ domain (Figure 3). Thus, MNT serves as a bridge
between MYC–MAX (the proliferative arm of the network) and MLX–MLXIP/MLXIPL
(the metabolic arm of the network) [37].
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Figure 3. The proxi al YC net ork and its interactions. protei s for di ers it and
bind DNA on E-boxes, generally activating transcription. All MXD proteins bind to MAX and MXD1,
and MXD4 and MNT also bind to MLX, activating or repressing gene transcription. MLX forms
complexes with MLXIP (MONDOA) and MLXIPL (MONDOB), binding on ChoRE (carbohydrate
response elements) and regulating metabolic genes. Notably, MAX and MNT form homodimers, as
represented in the Figure.
5. MNT Interactions Outside the Proximal MYC Network
5.1. SIN3 Proteins
SIN3A and SIN3B are transcriptional corepressors that recruit histone deacetylases
and other chromatin modifying enzymes, inhibiting transcription upon binding to E-boxes.
MNT represses transcription through direct interaction with the SIN3 proteins through the
SID, a domain in the N-termini that binds to the SIN3 s paired amphipathic helix (PAH2)
domain of SIN3B [3,22]. SIN3A and SIN3B, in turn, recruit histone deacetylases through
their histone interaction domain (HID) or co-factors including N-CoR, SDS3, SAP30, SAP18,
RBP1, or ING1/2 that work by bridging and stabilizing the complex and/or by enhancing
the chromatin remodeling activities [4,38]. In the case of MXD1, this is mediated by the
recruitment of HDAC1/3 by SIN3 [39]. The ability of MNT to block MYC-dependent
transformation and cell cycle progression is lost in SID mutants, indicating a close link
between biological function and repression [1,40].
5.2. REL
Recently, we identified the NF-κB family protein REL (also known as c-REL) as a
MNT interacting partner through the proteomic analysis of MNT co-immunoprecipitating
proteins in a MAX-independent setting. MNT acts as a repressor of the NF-κB pathway
by two suggested mechanisms: (i) the retention of REL in the cytoplasm in REL–MNT
complexes and (ii) the repression of REL target genes [41].
Once a stimulus is detected by the cell, the NF-κB pathway is activated and IκBα
is degraded. However, NF-κB also induces a negative feedback loop, leading to the
transcription of NFKBIA/IκBα. The newly synthesized IκBα enters the nucleus and shuttles
the NF-κB dimers back to the cytoplasm to terminate transcription [42–44]. MNT–REL
can bind and repress the NFKBIA/IκBα gene at least in some cell types. Therefore, MNT
might be acting to limit NF-κB activity in the absence of specific pathway activators. In
addition, the requirement of MNT for cell proliferation is dependent on REL in two cellular
models. This indicates that the pro-survival role of MNT can be mediated through REL.
Interestingly, MNT regulates the NF-κB pathway independently of MAX [41].
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5.3. MATα-1
Methionine adenosyltransferase a1 (MATα-1) forms a complex with MNT–MAX
in the normal liver and bile duct epithelial cells that binds E-boxes. In cholestasis and
cholangiocarcinoma cells, MATα-1-MNT interaction drops, and there is a switch towards
MYC and MAF protein complexes [45]. The switch from MNT–MAX to MYC–MAX during
cholestasis has been previously described, and it is responsible for p53 and cyclin D1
up-regulation and apoptosis [46].
5.4. Other Proteins
Recent studies have identified at least four other proteins as MNT interactors [41]:
CCDC6, AMPD2, QSER1, and TPP2. CCDC6 is involved in DNA damage response [47];
AMPD2 participates in purine metabolism as an AMP deaminase [48]; QSER1 has recently
been described as a demethylation regulator [49]; and TPP2 is a peptidase with roles in
antigen processing, lipid metabolism and CCK8 hormone regulation [50].
The main MNT functional interactions are represented in Figure 4A and include
NF-κB modulation by MNT in Figure 4B.
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recruits a HDAC comple and turns DNA into a closed conformation. MNT homodimers and MNT–
MAX and MNT–MLX heterodimers regulate transcription by binding DNA at E-boxes. MNT–REL
interaction results in NF-κB regulation by retaining REL dimers inactive in the cytoplasm and by
repressing REL target g nes hat w uld usually be activat d by REL. (B) O ce the cell receives an
NF-κB activation signal, the IKK complex is activated and is able to phosphorylate IκBα, which is
bound to REL-p50 dimers in the cytoplasm. This phosphorylation targets IκBα for ubiquitination
and posterior proteasomal degradation. Finally, the REL-p50 dimers are free to translocate into the
nucleus and regulate th ir t rget genes by binding to κB sites on he DNA. MNT f rms complexes
with REL and inhibits its functions.
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6. MNT Alterations in Cancer
MNT has been classified both as an oncogene or as a tumor suppressor gene based
on its diverse activities in the cells. The data arguing that it behaves as tumor suppressor
gene can be summarized as follows: (a) the tissue-specific loss of Mnt in mouse models
results in thymic lymphoma [51] or mammary tumors [27,52] (discussed below in point
7.1); (b) MEFs deficient in Mnt proliferate faster than wild-type cells and prematurely
enter into the S phase [27] (discussed below in point 7.1); (c) in a pan-cancer study of The
Cancer Genome Atlas (TCGA) data, heterozygous MNT deletion was found in 10% of the
tumors (overall frequency) and in more than 20% of liver hepatocellular carcinomas, lung
adenocarcinomas, sarcomas, and uterine carcinosarcomas [16].
The MNT locus at chromosome 17p13.3 is a hot spot for the loss of heterozygosity
(LOH) in tumors such as sporadic breast cancer, medulloblastomas, or chronic lymphocytic
leukemia (CLL) [21,53–55] as well as in ovarian cancer [56], astrocytomas [57], bladder
cancer [58], or osteosarcoma [59]. However, no inactivating mutations in MNT have been
found in these tumors. MNT deletions were also found in acute lymphoblastic leukemia [20],
and a decrease in its levels in medulloblastomas, which was caused by the haploinsufficiency
of chromosome 17p13.3 [21]. In the Sézary Syndrome, a malignant variant of cutaneous T-
cell lymphoma, more than 60% of the patients show a loss of one or both MNT alleles [17,18],
thus being the tumor with the highest frequency of MNT deletions. In agreement, the
down-regulation of MNT expression has also been reported in Sézary Syndrome [19].
The analysis of the genomic data available in TCGA shows that 0.6% of tumors carry
MNT mutations, with missense mutations being the most common. Most of these missense
mutations are observed in colorectal, endometrial, melanoma, esophagic, and head and
neck cancer. The majority of mutations map in the C-terminal half of the protein, i.e.,
downstream of the bHLHLZ domain.
Analysis of MNT mRNA expression in tumors shows that it is down-regulated in
tumor samples compared to their normal tissue counterparts, including testicular germ cell
tumors, uterine corpus endometrial carcinoma, and uterine carcinosarcoma. However, the
opposite occurs in other tumor types, including cervical carcinoma, cholangiocarcinoma,
acute myeloid leukemia, and pancreatic adenocarcinoma (Figure 5). These differences
likely reflect the complex biological activities of MNT, which depend on the cellular context
and the repertoire of proteins to interact with.
Cancers 2021, 13, x FOR PEER REVIEW 9 of 17 
 
 
bladder cancer [58], or osteosarcoma [59]. However, no inactivating mutations in MNT 
have been found in these tumors. MNT deletions were also found in acute lymphoblastic 
leukemia [20], and a decrease in its levels in medulloblastomas, which was caused by the 
haploinsufficiency of chromosome 17p13.3 [21]. In the Sézary Syndrome, a malignant var-
iant of cutaneous T-cell lymphoma, more than 60% of the patients show a loss of one or 
both MNT alleles [17,18], thus being the tumor with the highest frequency of MNT dele-
tions. In agreement, the down-regulation of MNT expression has also been reported in 
Sézary Syndrome [19]. 
The analysis of the genomic data available in TCGA shows that 0.6% of tumors carry 
MNT mutations, with missense mutations being the most common. Most of these mis-
sense mutations are observed in colorectal, endometrial, melanoma, esophagic, and head 
and neck cancer. The majority of mutations map in the C-terminal half of the protein, i.e., 
downstream of the bHLHLZ domain. 
Analysis of MNT mRNA expression in tumors shows that it is down-regulated in 
tumor samples compared to their normal tissue counterparts, including testicular germ 
cell tumors, uterine corpus endometrial carcinoma, and uterine carcinosarcoma. How-
ever, the opposite occurs in other tumor types, including cervical carcinoma, cholangio-
carcinoma, acute myeloid leukemia, and pancreatic adenocarcinoma (Figure 5). These dif-
ferences likely reflect the complex biological activities of MNT, which depend on the cel-
lular context and the repertoire of proteins to interact with. 
 
Figure 5. MNT can act as a tumor suppressor gene or oncogene depending on the tumor type. Gene expression profiling 
interactive analysis (GEPIA, http://gepia.cancer-pku.cn/, accessed on 7 July 2021) was performed to validate MNT mRNA 
expression in selected cancer type samples (in red) vs. normal samples (in grey). The expression data were first 
log2(TPM+1) transformed for differential analysis, and the log2FC was defined as median (tumor)–median (normal). Data 
are represented as mean ± SD (* p < 0.01). Abbreviations: CESC, cervical squamous cell carcinoma and endocervical ade-
nocarcinoma; CHOL, Cholangiocarcinoma; LAML, acute myeloid leukemia; PAAD, pancreatic adenocarcinoma; TGCT, 
testicular germ cell tumors; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma. 
7. Functions of MNT in the Cell 
MNT plays a pivotal role in controlling cell proliferation, differentiation, and cellular 
transformation. The cellular processes that MNT regulates are represented in Figure 6 and 
are described below. Its functions can result in either antagonism or cooperation with 
MYC. 
Figure 5. MNT can act as a tumor suppressor gene or oncogene depending on the tumor type. Gene expression profiling
interactive analysis (GEPIA, http://gepia.cancer-pku.cn/, accessed on 7 July 2021) was performed to validate MNT mRNA
expression in selected cancer type samples (in red) vs. normal samples (in grey). The expression data were first log2(TPM+1)
transformed for differential analysis, and the log2FC was defined as median (tumor)–median (normal). Data are represented
as mean ± SD (* p < 0.01). Abbreviations: CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma;
CHOL, Cholangiocarcinoma; LAML, acute myeloid leukemia; PAAD, pancreatic adenocarcinoma; TGCT, testicular germ
cell tumors; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.
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7. Functions of MNT in the Cell
MNT plays a pivotal role in controlling cell proliferation, differentiation, and cellular
transformation. The cellular processes that MNT regulates are represented in Figure 6 and
are described below. Its functions can result in either antagonism or cooperation with MYC.
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7.1. MNT as MYC Antagonist
The expression of MNT is ubiquitous, and its levels are constant throughout the cell
cycle. Thus, MNT–MAX dimers coexist with MYC–MAX dimers along all phases of the cell.
The antagonism between MNT and MYC is achieved at three different levels: (i) competi-
tion for forming complexes with MAX, as MNT and MYC show similar affinities towards
MAX; (ii) binding to the E-Boxes of their shared target genes; and (iii) the transcriptional
repression of genes that are normally activated by MYC–MAX [1,24]. In fact, it has been
hypothesized that a major role of MYC is to overcome MNT transcriptional repression
rather than its transactivation capacity (reviewed in [22]).
MNT–MYC counteraction was initially studied in wild-type mouse embryonic fi-
broblasts (wt MEFs) versus Mnt knockout fibroblasts (Mnt-/- MEFs). Mnt-deficient MEFs
proliferated faster and entered the S phase prematurely, which was accompanied by an
increase in Cdk4 and Ccne1 (Cyclin E) and a decrease in Myc. Mnt-/- MEFs have higher
apoptotic rates and can efficiently escape senescence compared to wt MEFs. Notably, Mnt-/-
MEFs can be transformed by oncogenic RAS alone, mimicking cells with Myc overexpres-
sion. The deletion of Myc in MEFs causes a proliferation arrest that can be partially rescued
by the simultaneous deletion of Mnt [27,60–62].
In serum-stimulated quiescent cells, Myc is induced at the G0 to G1 transition, whereas
Mnt levels remain constant. During this transition, there is a switch from Mnt–Max to
Myc–Max dimers, which activate cell cycle progression genes, such as Cdk4, Ccnd2 (Cyclin
D2), ODC, or E2F2. Both Mnt overexpression or Myc loss blocks cell cycle entry, suggesting
that the ratio of Mnt versus Myc levels could determine the quiescent or proliferative state
of the cell [62].
Additional data supporting a MYC–MNT antagonism derive from studies using mice
with the conditional deletion of Mnt in mammary tissue. This revealed an important role
of MNT in mammary epithelium development and tumorigenesis. These mice carry a
floxed Mnt gene and a Cre transgene under the control of the mouse mammary tumor virus
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(MMTV), which drives Cre expression in mammary epithelium. The conditional deletion
of Mnt in this model led to the formation of an adenocarcinoma with a tumor latency of
6–20 months, similar to the results of Myc overexpression in mammary epithelium. Indeed,
the mRNA expression patterns of mammary tumors resulting from Mnt deletion or Myc
overexpression were very similar [27,52].
The conditional deletion of MNT in T-cells caused an increase in both proliferation and
apoptosis. This was accompanied by tumor formation with a long latency, the disruption
of T-cell development, and the enlargement of the secondary lymphoid organs. There
was a modest increase in the expression of Cdk4 and the cyclins D2, E1, A, and B1 and a
slight downregulation of Bcl-2 and Bcl-xL. The polarized differentiation of CD4+ T cells
into Th1 (T-helper cell type 1) caused inflammation and, consequently, predisposition to
T-cell lymphoma [51,63].
Studies in Drosophila melanogaster also show similar MYC–MNT antagonism to the one
found in mouse models and in humans. Indeed, dMnt and dMyc have opposing activities
in cell growth in vivo [23,24]. There is an important overlap between the dMyc, dMnt, and
dMax DNA binding regions, revealing shared target genes. For instance, dMnt antagonized
the growth stimulatory effects of dMyc by downregulating pre-rRNA synthesis [64,65]. In
this model, dMnt overexpression rescued the viability and cell growth defects caused by
dMyc deletion.
However, both in mice [52] and in Drosophila [24], the overlap between Myc- and
Mnt-regulated genes is only partial. This has been attributed to at least two facts: (i) the
sequence of the bHLH domains and thus the affinities for DNA are not identical, and (ii)
whereas Myc can only bind to Max, Mnt may form at least three different complexes, as
discussed in Section 4.
Another proof of MNT and MYC antagonism is the response to hypoxia, a common
feature in solid tumors. During hypoxia there is an increase in HIF-1α and HIF-2α, which,
in turn, induce the expression of the microRNA miR-210. Since miR-210 downregulates
MNT, its levels are lower in hypoxia. Furthermore, MNT downregulation has caused a
switch to MYC–MAX dimers and the activation of MYC-target genes in several models.
Consequently, tumoral cells can override cell cycle arrest and apoptosis by releasing MNT–
MYC antagonism [46,66–68]. Hypoxia has an important impact on the cells, which is
in part because of the impairment of the circadian rhythm [69]. Apart from the roles of
HIF-1α and mTOR in the regulation of the transcriptional clock program, the disturbed
MYC/MAX/MNT balance can lead to changes in the expression of circadian rhythm
genes. In fact, MNT–MAX were recently described to bind to the PER2, CRY1, and CRY2
promoters [70].
MNT–MYC counteraction was also shown in a myeloid differentiation model de-
scribed by Kapoor and colleagues [30]. Treating HL60 cells with differentiating agents,
including all-trans retinoic acid, led to a decrease in E6AP and subsequently to a loss of
E6AP-mediated degradation of MNT. In this model, increased levels of MNT antagonized
MYC and induced cell cycle arrest followed by myeloid differentiation.
Niu et al. [71] described that MYC induced miR-378a-3p, which, in turn, down-
regulated MNT in Burkitt’s lymphoma. MNT reduction releases MNT–MYC antagonism
and enables the MYC-driven transformation process.
Altogether, these data support the role of MNT as a MYC antagonist and show how
MNT restricts the pro-proliferative activities of MYC.
7.2. MNT as MYC Cooperator
In contrast to the data presented above, MNT can also act as an oncogene cooperating
with Myc as: (a) T-cell-specific homozygous Mnt deletion prevented thymic lymphoma de-
velopment in mice overexpressing the Myc protein in T cells; (b) Mnt heterozygosity slowed
Myc-driven tumorigenesis; (c) Mnt deletion in homozygosis impairs lymphomagenesis in
Eµ-Myc mice.
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The pro-tumorigenic role of MNT is supported by its pro-survival functions, which
seem necessary for sustaining MYC activities. In the study of Link et al., Mnt was necessary
for Myc-driven thymic lymphomagenesis in mouse models [72]. Mnt knockout together
with Myc overexpression in the thymocytes resulted in higher apoptotic levels than in cells
with Mnt knockout or with Myc overexpression alone. This was not related to increased p53
but rather to enhanced levels of reactive oxygen species (ROS). Mnt deficient thymocytes
were highly sensitive to the inhibition of several ROS detoxification systems. This effect on
survival became worse when MYC levels increased, as shown by using models from no
MYC to endogenous levels and further to ectopic high MYC expression [73], which is in
line with the fact that that MYC-driven proliferation and apoptosis are triggered by certain
MYC thresholds. Consequently, MYC levels influence MYC outputs; thus, they determine
the differential need for MNT [73].
The pro-survival functions of MNT and its counteracting role on MYC were also
described in the response of T-cells to OX40, a T-cell costimulatory molecule from the
tumor-necrosis receptor ligand family [74]. This ligand produces an increase in Myc but
also in Mxd4 and Mnt. Myc drives T-cell proliferation while Mxd4 and Mnt evade cell
death inflicted by Myc excess.
Another study showed that Mnt heterozygosity slows down Myc-driven B and T-
lymphomagenesis in two Myc transgenic models, vavP-MYC10 mice, and Eµ-myc mice [75].
However, the exact mechanism was not defined, as the authors did not find changes in
the preleukaemic populations, cell size, cell cycle, apoptosis, or senescence of the murine
lymphoma cells. In a second study [76], Mnt was deleted in homozygosis using two Mnt
conditional knockdown models: the Mntfl/fl;Eµ-Myc/Rag1Cre and Mntfl/fl;Eµ-Myc/CreERT2
mice, to avoid the early embryonic lethality of homozygous Mnt deletion. In the Mntfl/fl;Eµ-
Myc/Rag1Cre model, the mice carried floxed Mnt alleles and the Rag1Cre35 transgene,
which allowed the expression of the Cre recombinase in lymphoid progenitor cells only.
In the Mntfl/fl;Eµ-Myc/CreERT2 model, the CreERT2 transgene encoded a Cre recombinase
fused to the modified hormone-binding domain of the estrogen receptor in the Rosa26 locus.
Thus, Cre recombinase expression can be induced by 4-hydroxy(4OH)-tamoxifen. Both
the Mntfl/fl;Eµ-Myc/Rag1Cre and Mntfl/fl;Eµ-Myc/CreERT2 models showed that Mnt loss
impairs the characteristic Myc-driven lymphomagenesis of Eµ-Myc mice, mainly affecting
the premalignant early B lineage cell proliferation. Mnt deletion also impaired normal
lymphopoiesis in wild-type mice, suggesting that MNT has an important role in B-cell
development. MNT anti-apoptotic functions must be key to compensate for increases in
MYC levels during lymphopoiesis. In MYC-driven B lymphomagenesis, the IL-7 receptor
signaling up-regulates both Mnt and Myc, and Mnt suppresses apoptosis by repressing
Bim thus facilitating MYC activity.
8. MAX-Independent Roles of MNT
MAX is an essential protein that supports the functions of the proximal MYC network,
as it is a shared partner between the MYC and MXD proteins. Little is known about the
function of these proteins in the absence of MAX. However, MAX is deleted in some cancers
of neuroendocrine origin, such as pheochromocytomas, paragangliomas, gastrointestinal
stromal tumors, and small cell lung cancer [77–81]. This raises the question of how MYC
and MXD proteins can conduct their functions without MAX.
We studied the MAX-independent functions of MNT using UR61 cells, which derive
from the rat pheochromocytoma PC12 cell line. PC12 cells express a truncated Max protein
that lacks helix 2, the leucine zipper, and the C-terminal region. Thus, Max in PC12
cannot homo- or heterodimerize, nor repress transcription [82]. In this model, we observed
that Mnt expression is higher in the absence of Max and that it distributes in both the
nucleus and the cytoplasm, in contrast to MAX-expressing cells, in which MNT is mostly
nuclear [1,2]. This is due to the negative regulation of Mnt–Max dimers over the Mnt
promoter. Thus, in the absence of Max, Mnt cannot autoregulate its expression and the
excess of Mnt spreads towards the cytoplasm. Max re-expression led to a decrease of Mnt
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levels, as Mnt–Max dimers repress the Mnt promoter. Interestingly, Mnt was required for
sustaining cell proliferation even in the absence of Max and regulated gene expression,
especially DNA damage and cell cycle genes, in a Max-independent way. We confirmed
Mnt–Mlx heterodimerization and Mnt homodimerization in UR61 cells. The latter had
only been shown in yeast two-hybrid assays and in vitro using recombinant proteins [1,2].
Chromatin immunoprecipitation (ChIP)-qPCR and ChIP-seq revealed that Mnt binds to the
DNA on E-boxes in the absence of Max. We also observed Mnt binding to fork head factors
sites, in accordance with a study on the coordinated regulation of MNT and FOXO of some
cell cycle control genes [83]. Some of the Mnt direct target genes that we detected were
BIRC5/Survivin, CDK1, BRCA1, ERCC6, and FBXO32, the latter of which was previously
described [83]. Despite this, we believe that in the absence of MAX, MNT binding to
the DNA is weaker, as the overall results of our ChIP-seq in Max-deficient cells was low
compared to other available ChIP-seq data for MNT in MAX-expressing cells (ENCODE
project) [35]. This is in line with results in wild-type and knockout Max B-cells, where the
genomic occupancy of Mnt decreases in the absence of Max, although it does not disappear,
as is the case for Myc [84].
As described above, MNT can form dimers with MLX, which, in turn, interact with
MLXIP and MLXIPL. These complexes play an important role in the regulation of the genes
involved in glycolytic and lipogenic metabolism by binding to ChoRE elements, which
are composed of two E-boxes separated by five nucleotides (Figure 3) [85]. Thus, it is
conceivable that MNT impinges on metabolism by modifying the levels of MLX available
for binding to MLXIP or MLXIPL.
9. Concluding Remarks and Therapeutical Perspectives
MYC has been one main focus of cancer research since it was identified in 1977–1979
as the oncogene captured by an avian oncogenic retrovirus [86–88] and was later found
deregulated in 70% of human tumors [89]. However, in recent years, the interest in
understanding the entire proximal MYC network has grown. The studies mentioned in
this review place MNT in a key position as a MYC modulator and demonstrate its diverse
and essential roles in cell biology (summarized in Figure 6).
The functions of MNT are generally connected to MYC. Yet, studies in MYC knockout
cells raised the question of whether MYC is a MNT antagonist rather than MNT a MYC
antagonist [22]. Mnt knockdown in Myc-deficient rat fibroblasts showed that Mnt also
conducts pro-survival functions in the absence of Myc [61]. Thus, the most important role
of MYC might be to relieve MNT-mediated repression rather than activating transcription.
In this scenario, MNT functions would remain unaffected by the presence or absence of
MYC, while excessive MYC levels would impact MNT by impairing its transcriptional
repressing activity.
The dual role of MNT in cancer, either as a MYC antagonist and or as a MYC co-
operator, offers the possibility of using MNT as a therapeutical target. For instance, in
MYC-driven lymphomas, tumor cells depend on MNT to survive. Thus, drugs that inhibit
MNT activities (e.g., impairing critical interactions) would increase the efficacy of current
therapies by enhancing apoptosis [76]. One possibility would be to test the MYC:MAX
inhibitors Omomyc, 10058-F4, 10074-G5, Mad, or MYCMI-6, 11, and 14 on MNT. Some
of these, such as Omomyc or Mad peptides, preferentially bind to MAX and not to MYC.
Hence, they might be used as MNT inhibitors by impairing MNT–MAX interaction. How-
ever, this possibility has not been formally addressed yet [89–93]. In addition, as MNT
downregulation stimulates NF-κB signaling through the interaction with REL (Figure 4B),
NF-κB inhibitors could be used in tumors with MNT loss, such as in CTCL (Table 1).
Further research will uncover new roles of MNT in cell biology and will provide strategies
for its use as a clinical target.
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